Compare Abeona Therapeutics Inc (ABEO) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vanguard Growth Index Fund ETF — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Vanguard Growth Index Fund ETF trades at $85.92. Which is the better fit depends on your goals.
| ABEO | VUG | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $90.29 |
52-Week Low | $4.17 | $70.00 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VUG trades at $86.68, up 1.38% on the day, with a bullish technical signal from moving averages but bearish oscillators. The ETF recently executed a 1:6 stock split on April 21, 2026, and declared a $0.09 dividend payable June 30, 2026. Support sits near $85–$86, with resistance at $87–$88. Media coverage highlights its low 0.04% expense ratio and strong performance against active funds, though technology concentration at 56% of assets poses sector risk.
Outlook remains positive given cost efficiency and growth exposure, but investors face volatility from tech reliance and market sentiment shifts. The fund's large-cap focus offers stability, yet macroeconomic pressures could challenge returns. Risks include sector rotation and valuation sensitivity, balanced by long-term growth potential in U.S. equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
